文献速递临床试验与 GCP基础与转化研究

自体富白细胞血小板纤维蛋白促进尼泊尔麻风溃疡愈合的个体随机疗效试验:TABLE试验方案

An individual randomised efficacy trial of autologous blood products, leukocyte and platelet-rich fibrin (L-PRF), to promote ulcer healing in leprosy in Nepal: the TABLE trial protocol.
PubMed 文献 · Trials · 2021-07-15

该方案拟在尼泊尔Anandaban医院单中心开展单盲个体随机对照试验,纳入130例18岁以上、足部慢性清洁干燥无感染溃疡(2–20 cm²)患者,比较L-PRF基质与生理盐水敷料在每周两次换药中的效果,主要结局为盲法观察者用标准化照片评估的愈合率及完全再上皮化时间,随访6个月。

要点

  • L-PRF组在每周两次换药时于溃疡床应用自体富白细胞血小板纤维蛋白基质。
  • 对照组的常规护理为每周两次换药时仅使用生理盐水敷料。
  • 主要结局为盲法评估的愈合率与完全再上皮化时间,随访至随机后6个月。

核心结论

  • 该试验旨在评估L-PRF治疗麻风溃疡的临床与成本效果,并评价其对患者生活质量的影响。

研究设计与样本

  • 单中心、单盲、个体随机对照试验,在尼泊尔加德满都Anandaban医院开展,计划纳入130例患者。

关键数值与推荐

  • 纳入标准为18岁及以上、因清洁干燥无感染的慢性足部溃疡(2–20 cm²)住院的患者。
  • 若溃疡感染,须先治疗感染再入组。
  • 干预为每周两次换药时在溃疡床应用L-PRF基质;对照为每周两次换药时仅用生理盐水敷料。
  • 主要结局为盲法观察者用标准化照片评估的愈合率及完全再上皮化时间,随访至随机后6个月。

临床怎么用

  • 该方案为L-PRF在麻风溃疡中的临床与成本效果评价提供随机对照证据框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Leprosy is curable with multidrug therapy and treatment in the early stages can prevent disability. However, local nerve damage can lead to injury and consequently recurring and disfiguring ulcers. The aim of this study is to evaluate the treatment of leprosy ulcers using an autologous blood product; leukocyte and platelet-rich fibrin (L-PRF) to promote healing. METHODS: This is a single-centre study in the Anandaban Hospital, The Leprosy Mission Nepal, Kathmandu, Nepal. Consenting patients (n=130) will be individually randomised in a single-blinded, controlled trial. Participants will be 18 years of age or older, admitted to the hospital with a clean, dry and infection-free chronic foot ulcer between 2 and 20 cm2 in size. If the ulcer is infected, it will be treated before enrolment into the study. The intervention involves the application of leukocyte and platelet-rich fibrin (L-PRF) matrix on the ulcer beds during twice-weekly dressing changes. Controls receive usual care in the form of saline dressings only during their twice-weekly dressing changes. Primary outcomes are the rate of healing assessed using standardised photographs by observers blind to allocated treatment, and time to complete re-epithelialization. Follow-up is at 6 months from randomisation. DISCUSSION: This research will provide valuable information on the clinical and cost-effectiveness of L-PRF in the treatment of leprosy ulcers. An additional benefit is the evaluation of the effects of treatment on quality of life for people living with leprosy ulcers. The results will improve our understanding of the scalability of this treatment across low-income countries for ulcer healing in leprosy and potentially other conditions such as diabetic ulcers. TRIAL REGISTRATION: ClinicalTrials.gov ISRCTN14933421 . Registered on 16 June 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Napit IB, Shrestha D, Bishop J, et al. An individual randomised efficacy trial of autologous blood products, leukocyte and platelet-rich fibrin (L-PRF), to promote ulcer healing in leprosy in Nepal: the TABLE trial protocol. Trials. 2021. PMID: 34266456. doi:10.1186/s13063-021-05392-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。